• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

作者信息

Maron Barry J, Maron Martin S, Sherrid Mark V, Rowin Ethan J

机构信息

Tufts Medical Center Hypertrophic Cardiomyopathy Center Boston MA.

NYU Grossman School of MedicineNYU Langone Health New York NY.

出版信息

J Am Heart Assoc. 2022 May 3;11(9):e024566. doi: 10.1161/JAHA.121.024566.

DOI:10.1161/JAHA.121.024566
PMID:35502772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9238594/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fa2/9238594/5cefe157f926/JAH3-11-e024566-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fa2/9238594/5cefe157f926/JAH3-11-e024566-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fa2/9238594/5cefe157f926/JAH3-11-e024566-g001.jpg

相似文献

1
Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.新型负性肌力药物在症状性梗阻性肥厚型心肌病既定手术心肌切除术时代的未来作用。
J Am Heart Assoc. 2022 May 3;11(9):e024566. doi: 10.1161/JAHA.121.024566.
2
Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy.梗阻性肥厚型心肌病行室间隔心肌切除术治疗后的心肌力学重构。
J Am Soc Echocardiogr. 2013 Aug;26(8):893-900. doi: 10.1016/j.echo.2013.05.012. Epub 2013 Jun 22.
3
Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Transcoronary and Endocardial Approach.肥厚性梗阻性心肌病的间隔消融术：经冠状动脉和心内膜途径
Am J Med Sci. 2016 Nov;352(5):466-471. doi: 10.1016/j.amjms.2016.08.025. Epub 2016 Sep 21.
4
Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy.心血管医学中的争议。对于有症状的梗阻性肥厚型心肌病患者，外科室间隔心肌切除术仍是主要的治疗选择。
Circulation. 2007 Jul 10;116(2):196-206; discussion 206. doi: 10.1161/CIRCULATIONAHA.107.691378.
5
Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation.肥厚型心肌病的室间隔心肌切除术：在酒精性室间隔消融术日益增多的时代的重要手术知识和技术要点
Gen Thorac Cardiovasc Surg. 2018 Apr;66(4):192-200. doi: 10.1007/s11748-018-0895-0. Epub 2018 Feb 15.
6
Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten?新型药物美曲莫特治疗的出现是否对手术肌切除术提出了挑战？
Asian Cardiovasc Thorac Ann. 2022 Jan;30(1):11-18. doi: 10.1177/02184923221074414. Epub 2022 Jan 24.
7
Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience.手术洞察：梗阻性肥厚型心肌病的室间隔心肌切除术——梅奥诊所的经验
Nat Clin Pract Cardiovasc Med. 2007 Sep;4(9):503-12. doi: 10.1038/ncpcardio0965.
8
Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy?在室间隔肌切除术时进行房颤消融是否能提高梗阻性肥厚型心肌病患者的生存率？
J Thorac Cardiovasc Surg. 2021 Mar;161(3):997-1006.e3. doi: 10.1016/j.jtcvs.2020.08.066. Epub 2020 Aug 25.
9
Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present.症状性梗阻性肥厚型心肌病外科心肌切除术60年的发展历程，从美国国立卫生研究院的历史手术经验到当前的见解
Am J Cardiol. 2022 Jun 1;172:107-108. doi: 10.1016/j.amjcard.2022.02.035. Epub 2022 Mar 28.
10
Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience.希腊肥厚型心肌病的外科室间隔心肌切除术：单中心初步经验。
Hellenic J Cardiol. 2014 Mar-Apr;55(2):132-8.

引用本文的文献

1
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.肥厚型心肌病诊断与治疗指南 - 2024
Arq Bras Cardiol. 2024 Jul 26;121(7):e202400415. doi: 10.36660/abc.20240415.
2
Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies.肥厚型心肌病：从药物治疗到晚期心力衰竭治疗。
Curr Cardiol Rep. 2024 Sep;26(9):985-994. doi: 10.1007/s11886-024-02095-6. Epub 2024 Jul 11.

本文引用的文献

1
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.肥厚型心肌病的诊断与评估：美国心脏病学会心血管造影与介入学会最新临床综述
J Am Coll Cardiol. 2022 Feb 1;79(4):372-389. doi: 10.1016/j.jacc.2021.12.002.
2
Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.症状性梗阻性肥厚型心肌病手术切除术后≥10年的随访结果
Am J Cardiol. 2022 Jan 15;163:91-97. doi: 10.1016/j.amjcard.2021.09.040. Epub 2021 Nov 14.
3
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
VALOR-HCM 研究的设计和原理：评估马卡塞特在有症状的梗阻性肥厚型心肌病成人患者中的疗效，这些患者有资格接受间隔减少治疗。
Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
5
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
6
Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story.左心室肥厚的消退对肥厚型心肌病患者真的是件好事吗？：新兴的马伐卡坦故事。
Am J Cardiol. 2021 May 15;147:145-146. doi: 10.1016/j.amjcard.2021.01.034. Epub 2021 Feb 4.
7
Mavacamten for hypertrophic obstructive cardiomyopathy.
Lancet. 2021 Jan 30;397(10272):369. doi: 10.1016/S0140-6736(20)32384-9.
8
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年美国心脏病学会/美国心脏协会肥厚型心肌病诊断和治疗指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告。
Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20.
9
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.马伐卡坦对梗阻性肥厚型心肌病的心脏结构有积极影响：EXPLORER-HCM心脏磁共振亚研究分析。
Circulation. 2021 Feb 9;143(6):606-608. doi: 10.1161/CIRCULATIONAHA.120.052359. Epub 2020 Nov 15.
10
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.